385 related articles for article (PubMed ID: 27087491)
41. Nanotechnology-based drug delivery systems for the treatment of Alzheimer's disease.
Fonseca-Santos B; Gremião MP; Chorilli M
Int J Nanomedicine; 2015; 10():4981-5003. PubMed ID: 26345528
[TBL] [Abstract][Full Text] [Related]
42. A novel monolithic controlled delivery system of resveratrol for enhanced hepatoprotection: nanoformulation development, pharmacokinetics and pharmacodynamics.
Singh A; Ahmad I; Ahmad S; Iqbal Z; Ahmad FJ
Drug Dev Ind Pharm; 2016 Sep; 42(9):1524-36. PubMed ID: 26902951
[TBL] [Abstract][Full Text] [Related]
43. Recent Developments in the Application of Polymeric Nanoparticles as Drug Carriers.
Moritz M; Geszke-Moritz M
Adv Clin Exp Med; 2015; 24(5):749-58. PubMed ID: 26768624
[TBL] [Abstract][Full Text] [Related]
44. Capsaicin-loaded folic acid-conjugated lipid nanoparticles for enhanced therapeutic efficacy in ovarian cancers.
Lv L; Zhuang YX; Zhang HW; Tian NN; Dang WZ; Wu SY
Biomed Pharmacother; 2017 Jul; 91():999-1005. PubMed ID: 28525949
[TBL] [Abstract][Full Text] [Related]
45. Sucrose ester stabilized solid lipid nanoparticles and nanostructured lipid carriers. I. Effect of formulation variables on the physicochemical properties, drug release and stability of clotrimazole-loaded nanoparticles.
Das S; Ng WK; Tan RB
Nanotechnology; 2014 Mar; 25(10):105101. PubMed ID: 24531790
[TBL] [Abstract][Full Text] [Related]
46. New methods for lipid nanoparticles preparation.
Corrias F; Lai F
Recent Pat Drug Deliv Formul; 2011 Sep; 5(3):201-13. PubMed ID: 21834772
[TBL] [Abstract][Full Text] [Related]
47. Development, Optimization, and Evaluation of Carvedilol-Loaded Solid Lipid Nanoparticles for Intranasal Drug Delivery.
Aboud HM; El Komy MH; Ali AA; El Menshawe SF; Abd Elbary A
AAPS PharmSciTech; 2016 Dec; 17(6):1353-1365. PubMed ID: 26743643
[TBL] [Abstract][Full Text] [Related]
48. Chapter 10 - Solid lipid nanoparticles and microemulsions for drug delivery The CNS.
Gasco MR; Priano L; Zara GP
Prog Brain Res; 2009; 180():181-92. PubMed ID: 20302835
[TBL] [Abstract][Full Text] [Related]
49. PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery.
Chan JM; Zhang L; Yuet KP; Liao G; Rhee JW; Langer R; Farokhzad OC
Biomaterials; 2009 Mar; 30(8):1627-34. PubMed ID: 19111339
[TBL] [Abstract][Full Text] [Related]
50. Does the commonly used pH-stat method with back titration really quantify the enzymatic digestibility of lipid drug delivery systems? A case study on solid lipid nanoparticles (SLN).
Heider M; Hause G; Mäder K
Eur J Pharm Biopharm; 2016 Dec; 109():194-205. PubMed ID: 27789354
[TBL] [Abstract][Full Text] [Related]
51. Factors affecting drug encapsulation and stability of lipid-polymer hybrid nanoparticles.
Cheow WS; Hadinoto K
Colloids Surf B Biointerfaces; 2011 Jul; 85(2):214-20. PubMed ID: 21439797
[TBL] [Abstract][Full Text] [Related]
52. The use of nanoparticulates to treat breast cancer.
Tang X; Loc WS; Dong C; Matters GL; Butler PJ; Kester M; Meyers C; Jiang Y; Adair JH
Nanomedicine (Lond); 2017 Oct; 12(19):2367-2388. PubMed ID: 28868970
[TBL] [Abstract][Full Text] [Related]
53. Silica encapsulated lipid-based drug delivery systems for reducing the fed/fasted variations of ziprasidone in vitro.
Dening TJ; Rao S; Thomas N; Prestidge CA
Eur J Pharm Biopharm; 2016 Apr; 101():33-42. PubMed ID: 26812284
[TBL] [Abstract][Full Text] [Related]
54. Recent advances in nanoparticle-mediated siRNA delivery.
Williford JM; Wu J; Ren Y; Archang MM; Leong KW; Mao HQ
Annu Rev Biomed Eng; 2014 Jul; 16():347-70. PubMed ID: 24905873
[TBL] [Abstract][Full Text] [Related]
55. Drug nanosuspensions: a ZIP tool between traditional and innovative pharmaceutical formulations.
Leone F; Cavalli R
Expert Opin Drug Deliv; 2015; 12(10):1607-25. PubMed ID: 25960000
[TBL] [Abstract][Full Text] [Related]
56. Computer-Assisted Drug Formulation Design: Novel Approach in Drug Delivery.
Metwally AA; Hathout RM
Mol Pharm; 2015 Aug; 12(8):2800-10. PubMed ID: 26107396
[TBL] [Abstract][Full Text] [Related]
57. Second world conference on nanomedicine and drug delivery.
Ninan N; Thomas S; George A; Sebastian M
Ther Deliv; 2011 Jun; 2(6):711-5. PubMed ID: 22822503
[TBL] [Abstract][Full Text] [Related]
58. Manufacturing of a Secretoneurin Drug Delivery System with Self-Assembled Protamine Nanoparticles by Titration.
Scheicher B; Lorenzer C; Gegenbauer K; Partlic J; Andreae F; Kirsch AH; Rosenkranz AR; Werzer O; Zimmer A
PLoS One; 2016; 11(11):e0164149. PubMed ID: 27828968
[TBL] [Abstract][Full Text] [Related]
59. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs?
Das S; Ng WK; Tan RB
Eur J Pharm Sci; 2012 Aug; 47(1):139-51. PubMed ID: 22664358
[TBL] [Abstract][Full Text] [Related]
60. Applications of lipid nanoparticles in gene therapy.
Del Pozo-Rodríguez A; Solinís MÁ; Rodríguez-Gascón A
Eur J Pharm Biopharm; 2016 Dec; 109():184-193. PubMed ID: 27789356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
